ArticleCancer2019
Sorafenib plus intensive chemotherapy improves survival in patients with newly diagnosed, FLT3-internal tandem duplication mutation-positive acute myeloid leukemia.
Article in Cancer, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 24 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
24 citing papers in PubMed.
- The Combination Therapy With Sorafenib in Therapeutic Strategy of Acute Myeloid Leukemia. Is It Promising? A Narrative Review.Health science reports · 2025Article
- Recent advancements in biomarkers, therapeutics, and associated challenges in acute myeloid leukemia.Annals of hematology · 2024Review
- Novel Therapeutic Targets in Acute Myeloid Leukemia (AML).Current oncology reports · 2024Review
- Article
- Impact of genetic patterns on sorafenib efficacy in patients with FLT3-ITD acute myeloid leukemia undergoing allogeneic hematopoietic stem cell transplantation: a multi-center, cohort study.Signal transduction and targeted therapy · 2023Article
- Retinoic acid and proteotoxic stress induce AML cell death overcoming stromal cell protection.Journal of experimental & clinical cancer research : CR · 2023Article
- Role of Gene Mutations in Acute Myeloid Leukemia: A Review Article.Global medical genetics · 2023Review
- Optimizing Treatment Options for Newly Diagnosed Acute Myeloid Leukemia in Older Patients with Comorbidities.Cancers · 2023Review
- Prediction of survival with lower intensity therapy among older patients with acute myeloid leukemia.Cancer · 2023Article
- Current Understanding ofCancers · 2023Review
- Therapeutic Advances in Immunotherapies for Hematological Malignancies.International journal of molecular sciences · 2022Review
- Prediction of survival with intensive chemotherapy in acute myeloid leukemia.American journal of hematology · 2022Article
- Which FLT3 Inhibitor for Treatment of AML?Current treatment options in oncology · 2022Review
- New Drugs Bringing New Challenges to AML: A Brief Review.Journal of personalized medicine · 2021Review
- Management Approach to Acute Myeloid Leukemia Leveraging the Available Resources in View of the Latest Evidence: Consensus of the Saudi Society of Blood and Marrow Transplantation.JCO global oncology · 2021Review
- Article
- FLT3 mutated acute myeloid leukemia: 2021 treatment algorithm.Blood cancer journal · 2021Review
- The effects of solution-focused nursing on leukemia chemotherapy patients' moods, cancer-related fatigue, coping styles, self-efficacy, and quality of life.American journal of translational research · 2021Article
- Review
- Clinical practice recommendation on hematopoietic stem cell transplantation for acute myeloid leukemia patients withHaematologica · 2020Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
19 authors.
Funding
Abstract
backgroundThe addition of midostaurin to induction chemotherapy improves survival in younger patients with newly diagnosed, FLT3-mutated acute myeloid leukemia (AML). Sorafenib is a potent multikinase inhibitor with efficacy when given as monotherapy. The authors investigated whether the addition of sorafenib to intensive induction chemotherapy improves outcomes in patients with FLT3-internal tandem duplication (ITD)-mutated AML.
methodsIn total, 183 patients who were newly diagnosed with FLT3-ITD-mutated AML between February 2001 and December 2017 were identified. Of these, 79 patients (43%) underwent intensive chemotherapy with the addition of sorafenib, and 104 (57%) received intensive chemotherapy alone. Propensity score matching identified 42 patients in each cohort.
resultsThe overall response rate was 98% in the sorafenib cohort and 83% in the intensive chemotherapy cohort (P = .057). The median follow-up was 54 months. The median event-free survival was 35 months in the sorafenib cohort and 8 months in the intensive chemotherapy cohort (P = .019), and the median overall survival was 42 and 13 months, respectively (P = .026). With censoring at the time of allogeneic stem cell transplantation, the median event-free survival was 31 and 8 months in the sorafenib and intensive therapy cohorts, respectively (P = .031), and the median overall survival was not reached and 10 months, respectively (P = .001). Multivariate Cox proportional hazards models confirmed that treatment with sorafenib was a favorable prognostic factor (P = .009; hazard ratio, 0.558; 95% CI, 0.360-0.865).
conclusionsThe addition of sorafenib improves survival in patients with FLT3-ITD-mutated AML regardless of whether they undergo allogeneic stem cell transplantation.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.